- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.11. | Transcode Therapeutics, Inc. - 8-K, Current Report | 9 | SEC Filings | ||
| 05.11. | TransCode Therapeutics gets Nasdaq extension to regain compliance | 8 | Seeking Alpha | ||
| 05.11. | TransCode Therapeutics maintains Nasdaq listing with conditions | 14 | Investing.com | ||
| 05.11. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance | 88 | GlobeNewswire (Europe) | BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced... ► Artikel lesen | |
| 10.10. | TransCode Therapeutics, Inc.: TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology | 132 | GlobeNewswire (Europe) | Patients currently remain on study for continued treatment with TTX-MC138 No significant safety or dose limiting toxicities reportedTTX-MC138, an antisense oligonucleotide conjugated to TransCode's... ► Artikel lesen | |
| 27.09. | Transcode Therapeutics droht Delisting von der Nasdaq | 16 | Investing.com Deutsch | ||
| 27.09. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.09. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate | 120 | GlobeNewswire (Europe) | Two patients dosed; several additional patients screened for enrollmentTrial to evaluate safety and tolerability of TTX-MC138 in patients with metastatic cancerTTX-MC138 is an antisense oligonucleotide... ► Artikel lesen | |
| 05.09. | TransCode Therapeutics secures $2M grant for lead candidate | 3 | Seeking Alpha | ||
| 05.09. | TransCode Therapeutics, Inc.: TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate | 3 | GlobeNewswire (USA) | ||
| 28.08. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.08. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.08. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation | 277 | GlobeNewswire (Europe) | Two clinical trial sites activatedPatient enrollment expected this quarterTrial designed to evaluate the safety and preliminary anti-tumor activity of TTX-MC138 BOSTON, Aug. 15, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 14.08. | Transcode Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | Transcode Therapeutics stock hits 52-week low at $0.23 | 2 | Investing.com | ||
| 24.07. | TransCode Therapeutics announces closing of public offering | 1 | Seeking Alpha | ||
| 24.07. | TransCode Therapeutics, Inc. Announces Closing of Public Offering | 1 | GlobeNewswire (USA) | ||
| 24.07. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.07. | Why Transcode Therapeutics (RNAZ) Stock Is Down 60% | 3 | Benzinga.com | ||
| 23.07. | Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today? | 3 | InvestorPlace |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,045 | +2,05 % | Qiagen NV-Aktie büßt 0,31 Prozent ein (39,06 €) | Im Minus liegt zur Stunde der Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 39,06 Euro. An der Börse liegt die Qiagen NV-Aktie aktuell im Minus. Das Papier verbilligte sich um 12 Cent. Das Wertpapier... ► Artikel lesen | |
| NOVAVAX | 8,130 | +0,02 % | NOVAVAX INC - 8-K, Current Report | ||
| MOLOGEN | - | - | EQS-News: Schutzgemeinschaft der Kapitalanleger e.V.: Inhaber der Anleihe WSV 2017/2015 der Mologen AG (ISIN DE000A2DANN4 / WKN A2DANN) mit Beständen bis zu 5.000 Euro Nominalwert können anteilige Vergütung des Gemeinsamen Vertreters zurückerhalten | Emittent / Herausgeber: Schutzgemeinschaft der Kapitalanleger e.V.
/ Schlagwort(e): Anleihe/Sonstiges
Inhaber der Anleihe WSV 2017/2015 der Mologen AG (ISIN DE000A2DANN4 / WKN... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,949 | +2,59 % | Palatin Technologies Inc. Loss At -$7.82 Mln In Q1 | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced Loss for first quarter of -$7.82 millionThe company's earnings totaled -$7.82 million, or -$0.39 per share. This compares with... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 3,890 | -0,89 % | The Analyst Landscape: 4 Takes On Inovio Pharmaceuticals | ||
| COSCIENS BIOPHARMA | 2,580 | -9,79 % | COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs | Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE... ► Artikel lesen | |
| XOMA ROYALTY | 28,600 | -1,38 % | Spotlight Stock Market: Market Notice 237/24 - Xoma AB will be listed on Spotlight Stock Market on November 22, 2024 | ||
| T2 BIOSYSTEMS | 0,500 | +2,25 % | T2 Biosystems To Sell Its FDA-Cleared Blood Diagnostics For Detection Of Sepsis-Causing Pathogens | WASHINGTON (dpa-AFX) - T2 Biosystems, Inc. (TTOO) Monday said it has reached a multi-year exclusive U.S. agreement with Cardinal Health (CAH) to sell its FDA-cleared direct-from-blood diagnostics... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,470 | -2,37 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study | --Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| ORAGENICS | 0,280 | +3,47 % | OGEN-Aktie stürzt auf 52-Wochen-Tief von 0,28 US-Dollar | ||
| FRESH TRACKS THERAPEUTICS | 0,730 | 0,00 % | Fresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company | ||
| LADRX | - | - | LadRx Corp - 10-Q, Quarterly Report | ||
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative... ► Artikel lesen | |
| EDESA BIOTECH | 2,080 | +2,97 % | Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results | TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases... ► Artikel lesen |
Das Unternehmen TRANSCODE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,373 Euro und damit -1,74 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.
